Mogamulizumab Improves Quality of Life in Real-World MF and SS Study

New data from the real-world PROSPER study (NCT05455931) demonstrate that mogamulizumab (Poteligeo) provides clinically meaningful and sustained improvements in symptoms and health-related quality of life (HRQoL) for adult patients living with mycosis fungoides (MF) and Sézary syndrome (SS).

Presented at the 6th World Congress of Cutaneous Lymphomas and detailed in a news release the findings underscore the treatment's impact on debilitating symptoms such as chronic itch, sleep disturbances, and impaired body temperature regulation.

For oncology nurses, who are often the first line of defense in managing the complex symptom burden of cutaneous T-cell lymphoma (CTCL), these real-world results offer a clearer picture of the patient experience beyond traditional clinical trial endpoints.

The burden of MF and SS

MF and SS are rare subtypes of CTCL that primarily affect the skin but can progress to involve the blood, lymph nodes, and internal organs. These conditions often present as painful or itchy plaques, tumors, or erythroderma (redness of the entire skin).

"Cutaneous T-cell lymphoma can affect far more than just the skin, impacting how patients feel and function every day," stated professor Julia Scarisbrick, Principal Investigator and Honorary Professor of Dermatology at University Hospitals Birmingham NHS Foundation Trust, in a statement from the news release.

The PROSPER study design

The PROSPER study was an observational, real-world study involving 73 patients with relapsed or refractory MF (n=41) or SS (n=32). To capture the lived experience of these patients, researchers utilized several patient-reported outcome (PRO) tools, including a CTCL-specific symptom diary, the MF/SS-CTCL-QoL questionnaire, and the Brief Fatigue Inventory (BFI).

Notably, the study was designed with direct input from patients and caregivers to ensure the data collected, such as difficulty regulating body temperature, were truly relevant to those living with the disease. Susan Thornton, study author and co-CEO of the Cutaneous Lymphoma Foundation, noted in the news release that "collaboration between industry and the patient community is essential to designing studies that generate more relevant insights into symptom burden."

Key findings: Rapid and sustained relief

One of the most encouraging aspects of the PROSPER data for nursing practice is the speed of symptom relief. Patients reported clinically meaningful improvements in skin itch, flaking, and redness as early as week 4 of treatment. These improvements were not only rapid but also durable, with gains sustained throughout the 48-week study period.

Beyond skin-specific symptoms, the study highlighted significant improvements in holistic wellness. By week 48, 30% of patients reported at least a 2-point improvement in sleep, and 37% reported better body temperature regulation. While fatigue scores remained relatively stable for patients with MF, those with SS experienced significant improvements in total BFI scores by the end of the study.

Clinical considerations for oncology nurses

While the PROSPER study highlights the benefits of mogamulizumab, oncology nurses must remain vigilant regarding the drug's safety profile. Mogamulizumab is indicated for adults with relapsed or refractory MF or SS after at least one prior systemic therapy.

Nurses should monitor patients for skin rashes throughout treatment. In previous clinical trials, the median time to onset for dermatologic toxicity was 15 weeks, though some cases occurred after 31 weeks. Treatment should be interrupted for moderate or severe (Grade 2 or 3) rashes and permanently discontinued for life-threatening (Grade 4) reactions or Stevens-Johnson syndrome (SJS).

Most infusion reactions occur during or shortly after the first infusion, though they can occur subsequently. Close monitoring is required; infusions should be interrupted for any grade of reaction and permanently discontinued for Grade 4 reactions.

Patients should also be monitored for signs of infection and autoimmune complications. Additionally, there is an increased risk of transplant-related complications for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) after receiving mogamulizumab.

Reference

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome. News release. June 29, 2026. Accessed June 30, 2026.